#United States #Boston #TTX-MC138 #TransCode Therapeutics #RNA oncology

TransCode Therapeutics Launches Direct Offering

On March 23, 2025, TransCode Therapeutics, Inc., a company specializing in RNA oncology, revealed plans for a registered direct offering priced under Nasdaq guidelines. The offering aims to raise essential funds to expedite their battle against cancer through advanced RNA therapeutics.

Details of the Offering

TransCode is set to sell 10,250,000 shares of its common stock along with warrants allowing purchases of the same number of shares, all priced at $0.98 each. The warrants come with an exercise price of $0.86 per share and will be immediately exercisable for five years from the issuance date. The anticipated closing date for this offering is March 25, 2025, contingent upon the fulfillment of standard closing conditions.

By executing this offering, TransCode expects to gather approximately $10 million in gross proceeds, before deductions for placement agent fees and other associated costs. This influx of capital is poised to significantly bolster the company's ongoing product development activities, particularly clinical trials involving TTX-MC138, TransCode’s leading therapeutic candidate. These trials are crucial for advancing the understanding and treatment of metastatic disease, which sadly remains one of the most challenging aspects of cancer management.

Funding Allocations

Specifically, the funds will be channeled towards multiple clinical trials tied to TTX-MC138, which targets metastatic tumors with high levels of microRNA-10b. This microRNA is a well-studied biomarker associated with metastasis and holds promise for creating more efficient treatment avenues for cancer patients. In addition to trial funding, the company plans to allocate resources for working capital and various corporate purposes, ensuring operational stability during this crucial phase.

The Role of ThinkEquity

ThinkEquity serves as the exclusive placement agent for this offering, leveraging its extensive network and expertise to facilitate a successful capital raise. Furthermore, the securities involved in this offering are being articulated under a shelf registration statement, having been previously filed with the U.S. Securities and Exchange Commission (SEC).

Investors looking for more information on these securities can access a supplementary prospectus that will be filed with the SEC. Detailed insights, including the offering's terms and associated risks, will be made available on the SEC's official website, further enhancing transparency for potential investors.

TransCode Therapeutics’ Mission

TransCode is on a mission to combat cancer through its innovative RNA therapeutic platform, which integrates advanced nanoparticle delivery systems capable of overcoming the inherent challenges of RNA delivery. By focusing on unique biomarkers and exhibiting a commitment to cutting-edge research, TransCode is well-positioned to navigate the complexities of modern cancer therapy.

Their lead candidate, TTX-MC138, has shown significant promise and underscores the company’s dedication to transformative cancer treatment solutions. Beyond TTX-MC138, TransCode is developing a portfolio that includes several groundbreaking RNA therapeutics designed to target a wide array of genetic abnormalities.

Looking Ahead

The recent fundraising announcement pushes TransCode into a pivotal moment that could establish new benchmarks in RNA-based cancer therapies. As the world stands at the brink of significant advancements in oncology, the successful conclusion of this offering is anticipated to accelerate TransCode's innovations and potentially reshape the future landscape of cancer treatment. Stakeholders and patients alike will be keeping a close eye on the outcomes of these clinical trials, as they hold the promise of hope for many battling cancer.

This announcement is crucial in the broader context of the fight against cancer, signifying a step toward more effective treatments through strategic funding and robust clinical research. Interested parties are encouraged to stay tuned for further developments as TransCode progresses with its ambitious agenda to enable more effective cancer solutions.